YAP1 and gastric cancer: For example, verteporfin, Sitagliptin and amphiregulin (AREG) are several promising anti-GC drugs, targeting to inhibit the activation of the key Hippo pathway effector YAP (Qiao et al., 2018; Yong et al., 2021).